Citations

Showing 10 of 108083 citations.

Exercise training-induced modification of the gut microbiota persists after microbiota colonization and attenuates the response to chemically-induced colitis in gnotobiotic mice
Allen, Jacob M. , Mailing, Lucy J., Cohrs, Josh, Salmonson, Charles E., Fryer, John Denis , Nehra, V., Hale, Vanessa L. , Kashyap, Purna , White, Bryan A. , Woods, Jeffrey A.

Mayo Clinic

Gut Microbes | September 1, 2017 | Volume: 9 | Issue: 2 | Pages: 115-130

10.1080/19490976.2017.1372077 | PMID 28862530 Get It

Fremanezumab as Add‐On Treatment for Patients Treated With Other Migraine Preventive Medicines
Cohen, Joshua M. , Yang, Ronghua , Newman, Lawrence C. , Aycardi, Ernesto, Bigal, Marcelo E. , Dodick, David W. , Li, Thomas

Mayo Clinic

Headache: The Journal of Head and Face Pain | September 1, 2017 | Volume: 57 | Issue: 9 | Pages: 1375-1384

10.1111/head.13156 | PMID 28862758 Get It

Background Fremanezumab (formerly TEV‐48125) is a monoclonal antibody directed against calcitonin‐gene‐related peptide (CGRP), a validated target for migraine preventive therapy. In two previous phase 2 studies, fremanezumab administered once every 28 days for 12 weeks was found to be effective and safe as a preventive treatment for patients suffering from episodic migraine (EM) and chronic migraine (CM). Objective To evaluate the efficacy and safety of fremanezumab as an add‐on preventive therapy in individuals with EM and CM who are on stable doses of preventive migraine medications. Methods Two randomized placebo‐controlled studies tested once‐monthly subcutaneous injections of various dosing regimens of fremanezumab versus placebo in EM and CM. Headache information was captured daily using an electronic headache diary. For these post hoc analyses, data were pooled from patients who were on stable preventive medications and taking fremanezumab doses of 225 mg or 675/225 mg, or placebo. Results The sample consisted of 133 patients, (67 fremanezumab and 66 placebo). Total reduction in migraine days for the duration of the study was 12.4 for fremanezumab and 7.4 for placebo ( P = .0321). There were also decreases in moderate/severe headache days (12.5 vs 7.1, P = .0058), and days using acute medication for headaches relative to placebo (11.6 vs 7.5, P = .0414). Treatment emergent adverse events were generally mild and transient, and no serious adverse events were considered to be treatment‐related by the site investigators. Conclusions The findings from these post hoc analyses suggest that fremanezumab is a safe and effective add‐on treatment for migraine patients being concomitantly treated with other migraine preventive medications. Trials are registered at Clinicaltrials.gov NCT02025556 and NCT02021773.
Performance of individually measured vs population‐based C ‐peptide kinetics to assess β‐cell function in the presence and absence of acute insulin resistance
Varghese, Ron T. , Man, Chiara Dalla , LAURENTI, MARCELLO C. , Piccinini, Francesca, Sharma, Anu , Bailey, Kent R. , Rizza, Robert A., Vella, Adrian , Vella, Adrian , Dalla Man, Chiara , Shah, Mithun V , Cobelli, Claudio

Mayo Clinic

Diabetes, Obesity and Metabolism | September 1, 2017 | Volume: 20 | Issue: 3 | Pages: 549-555

10.1111/dom.13106 | PMID 28862812 Get It

Aims To compare the performance of population‐based kinetics with that of directly measured C‐peptide kinetics when used to calculate β‐cell responsivity indices, and to study people with and without acute insulin resistance to ensure that population‐based kinetics apply to all conditions where β‐cell function is measured. Methods Somatostatin was used to inhibit endogenous insulin secretion in 56 people without diabetes. Subsequently, a C‐peptide bolus was administered and the changing concentrations were used to calculate individual kinetic measures of C‐peptide clearance. In addition, the participants were studied on 2 occasions in random order using an oral glucose tolerance test (OGTT). On one occasion, free fatty acid elevation, to cause insulin resistance, was achieved by infusion of Intralipid + heparin. The Disposition Index (DI) was then estimated by the oral minimal model using either population‐based or individual C‐peptide kinetics. Results There were marked differences in the exchange variables ( k 12 and k 21 ) of the model describing C‐peptide kinetics, but smaller differences in the fractional clearance; that is, the irreversible loss from the accessible compartment ( k 01 ), obtained from population‐based estimates compared with experimental measurement. Because it is predominantly influenced by k 01 , DI estimated using individual kinetics correlated well with DI estimated using population‐based kinetics. Conclusions These data support the use of population‐based measures of C‐peptide kinetics to estimate β‐cell function during an OGTT.
Unravelling hypothyroidism in AL amyloidosis: Authors' reply
Muchtar, Eli , Gertz, MA, Muchtar, E

Mayo Clinic

Journal of Internal Medicine | September 1, 2017 | Volume: 283 | Issue: 1 | Pages: 108-108

10.1111/joim.12681 | PMID 28861923 Get It

Click here to view the Letter to the Editor by Dr. Benvenga and Guarneri
How Can We Encourage Medical Student Interest in Psychiatric Careers?
Krahn, Lois E.

Mayo Clinic

American Journal of Psychiatry | September 1, 2017 | Volume: 174 | Issue: 9 | Pages: 823-824

10.1176/appi.ajp.2017.17050538 | PMID 28859506 Get It

Strabismus Incidence in a Danish Population-Based Cohort of Children
Torp‐Pedersen, Tobias , Boyd, Heather A. , Skotte, Line , Haargaard, Birgitte, Wohlfahrt, Jan , Holmes, Jonathan M. , Melbye, Mads , Holmes, Jonathan M.

Mayo Clinic

JAMA Ophthalmology | September 1, 2017 | Volume: 135 | Issue: 10 | Pages: 1047

10.1001/jamaophthalmol.2017.3158 | PMID 28859196 Get It

Quality Improvement Initiative to Reduce Pediatric Intensive Care Unit Noise Pollution With the Use of a Pediatric Delirium Bundle
Kawai, Yu , Weatherhead, Jeffrey , Traube, Chani , Owens, Tonie, Shaw, B., Fraser, Erin J., Scott, Annette, Wojczynski, Melody R., Slaman, Kristen L., Cassidy, Patty M., Baker, Laura A. , Shellhaas, Renée A. , Dahmer, Mary K. , Shever, Leah L. , Malas, Nasuh , Niedner, Matthew , Shellhaas, Renée A , Kawai, Yu

Mayo Clinic

Journal of Intensive Care Medicine | September 1, 2017 | Volume: 34 | Issue: 5 | Pages: 383-390

10.1177/0885066617728030 | PMID 28859578 Get It

Objectives: Noise pollution in pediatric intensive care units (PICU) contributes to poor sleep and may increase risk of developing delirium. The Environmental Protection Agency (EPA) recommends <45 decibels (dB) in hospital environments. The objectives are to assess the degree of PICU noise pollution, to develop a delirium bundle targeted at reducing noise, and to assess the effect of the bundle on nocturnal noise pollution. Methods: This is a QI initiative at an academic PICU. Thirty-five sound sensors were installed in patient bed spaces, hallways, and common areas. The pediatric delirium bundle was implemented in 8 pilot patients (40 patient ICU days) while 108 non-pilot patients received usual care over a 28-day period. Results: A total of 20,609 hourly dB readings were collected. Hourly minimum, average, and maximum dB of all occupied bed spaces demonstrated medians [interquartile range] of 48.0 [39.0-53.0], 52.8 [48.1-56.2] and 67.0 [63.5-70.5] dB, respectively. Bed spaces were louder during the day (10AM to 4PM) than at night (11PM to 5AM) (53.5 [49.0-56.8] vs. 51.3 [46.0-55.3] dB, P < 0.01). Pilot patient rooms were significantly quieter than non-pilot patient rooms at night (n=210, 45.3 [39.7-55.9]) vs. n=1841, 51.2 [46.9-54.8] dB, P < 0.01). The pilot rooms compliant with the bundle had the lowest hourly nighttime average dB (44.1 [38.5-55.5]). Conclusions: Substantial noise pollution exists in our PICU, and utilizing the pediatric delirium bundle led to a significant noise reduction that can be perceived as half the loudness with hourly nighttime average dB meeting the EPA standards when compliant with the bundle.
Randomized Controlled Trial Comparing Three Different Modalities of Lithotrites for Intracorporeal Lithotripsy in Percutaneous Nephrolithotomy
York, Nadya , Borofsky, Michael S. , Dauw, Casey A. , Paterson, Ryan F. , Denstedt, John D. , Razvi, Hassan , Nadler, Robert B., Humphreys, Mitchell R. , Preminger, Glenn M. , Nakada, Stephen Y., Krambeck, Amy E. , Miller, Nicole L. , Terry, Colin, Rawlings, Lori D., Lingeman, James E., Chew, Ben H. , Miller, Nicole L

Mayo Clinic

Journal of Endourology | September 1, 2017 | Volume: 31 | Issue: 11 | Pages: 1145-1151

10.1089/end.2017.0436 | PMID 28859485 Get It

Clinical Outcomes in Revision Anterior Cruciate Ligament Reconstruction: A Meta‐analysis
Mohan, Rohith , Webster, Kate E., Johnson, Nick R., Hewett, Timothy E. , Krych, Aaron J. , Krych, Aaron J , Stuart, Michael J.

Mayo Clinic

Arthroscopy | September 1, 2017 | Volume: 34 | Issue: 1 | Pages: 289-300

10.1016/j.arthro.2017.06.029 | PMID 28866344 Get It

Purpose The purpose of this meta‐analysis was to determine overall objective graft failure rate, failure rate by graft type (allograft vs autograft reconstruction), instrumented laxity, and patient outcome scores following revision anterior cruciate ligament (ACL) reconstruction. Outcomes of interest were collected for all studies meeting the study inclusion criteria, but lower‐level studies (level III/IV) were not pooled for quantitative synthesis due to high levels of heterogeneity in these study populations. Methods A comprehensive search strategy was performed to identify studies reporting outcomes of revision ACL reconstruction. The primary outcome reported was graft failure. A meta‐analysis comparing rate of failure by graft type was conducted using a random effects model. Studies also reported patient clinical outcome scores, including International Knee Documentation Committee (IKDC), Lysholm, and knee injury and osteoarthritis outcome scores (KOOS) and graft laxity. Results Eight studies with 3,021 patients (56% male, 44% female) with an average age of 30 ± 4 years and mean follow‐up time of 57 months were included. The overall objective failure rate was 6% (95% confidence interval [CI], 1.8%‐12.3%). Mean instrumented laxity as side‐to‐side difference was 2.5 mm (95% CI, 1.9‐3.1 mm). Mean IKDC subjective score was 76.99 (95% CI, 76.64‐77.34), mean KOOS symptoms score was 76.73 (95% CI, 75.85‐77.61), and mean Lysholm score was 86.18 (95% CI, 79.08‐93.28). The proportion of patients with IKDC grade A or B was 85% (95% CI, 77%‐91%). When the available data for failure rate were analyzed by graft type, autograft reconstruction had a failure rate of 4.1% (95% CI, 2.0%‐6.9%), similar to allograft reconstruction at 3.6% (95% CI, 1.4%‐6.7%). Conclusions In this meta‐analysis, revision ACL reconstruction had failure rates similar to autograft or allograft reconstruction. Overall outcome scores for revision reconstruction have improved but appear modest when compared with primary ACL reconstruction surgery. Level of Evidence Meta‐analysis of Level II studies, Level II.